Mhealth Supported Bundle to Improve Vaccination Completion
Implementing a Mobile Health Supported Bundle to Improve Routine Vaccination Completion Rate in a Low-resource Setting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Osayame A Ekhaguere, MBBS, MPH
- Phone Number: (317) 944 3691
- Email: osaekhag@iu.edu
Study Contact Backup
- Name: Rosena O Oluwafemi, MBCHB, MPH
- Phone Number: +2348034101163
- Email: bankyfem@yahoo.com
Study Locations
-
-
Ondo State
-
Akure, Ondo State, Nigeria, 1111
- Mother and Child Hospital Akure
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All parents or caregivers of patients who bring their child to the vaccine clinic to receive immunization for their first vaccine visit.
Exclusion Criteria:
- Parents or caregivers not willing to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Prospectively received appointment reminders, motivational interviews and targeted vaccine drives.
|
Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DPT3 vaccine completion rate
Time Frame: 15 Months
|
The proportion of enrolled subjects who complete the Diphtheria, pertussis, and tetanus vaccine (DPT3) vaccine series when assessed at 15 months of age.
|
15 Months
|
|
Measles vaccine completion rate
Time Frame: 15 Months
|
The proportion of enrolled subjects who complete the measles vaccine series when assessed at 15 months of age.
|
15 Months
|
|
Number of eligible subjects enrolled
Time Frame: 15 Months
|
Vaccine clinic records will be reviewed to identify the total number of eligible patients in the clinic (defined as those presenting to the vaccine clinic with a child receiving their first vaccine) and the number who agreed to participate during the study period.
|
15 Months
|
|
Project Cost
Time Frame: 15 Months
|
The cost of administering each component of the mHealth bundle will be documented, such as cost of targeted drive and cost of real time phone calls.
This will assist in determining the cost to scale the project.
|
15 Months
|
|
Provider Adoption
Time Frame: 15 Months
|
A modified intervention acceptability, perception and system usability assessment using a Likert scale questionnaire.
|
15 Months
|
|
Protocol Adherence
Time Frame: 15 Months
|
The proportion of eligible subjects who received a real-time phone call reminder, counselling, and targeted vaccine drive when indicated
|
15 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Osayame A Ekhaguere, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15107 (CTSRMC, Abramson Cancer Center, University of Pennsylvania)
- UL1TR002529 (U.S. NIH Grant/Contract)
- KL2TR002530 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.